Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (NASDAQ: AKBA), Array Biopharma (NASDAQ: ARRY) and Phibro Animal Health (NASDAQ: PAHC)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akebia Therapeutics (NASDAQ: AKBA), Array Biopharma (NASDAQ: ARRY) and Phibro Animal Health (NASDAQ: PAHC) with bullish sentiments.

Akebia Therapeutics (NASDAQ: AKBA)

In a report released today, Michael King from JMP Securities reiterated a Buy rating on Akebia Therapeutics (NASDAQ: AKBA). The company’s shares opened today at $8.83.

According to TipRanks.com, King is a 2-star analyst with an average return of 0.5% and a 45.1% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.

Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.

Array Biopharma (NASDAQ: ARRY)

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Array Biopharma (NASDAQ: ARRY) yesterday and set a price target of $13. The company’s shares opened today at $6.66, close to its 52-week high of $7.27.

Goldstein wrote:

“COLUMBUS Part I Delivered. Top-line data released earlier this year showed that the trial, in BRAF melanoma, demonstrated PFS of 14.9 months for the combination of binimetinib plus encorafenib, versus 7.3 months for vemurafenib alone.”

According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.7% and a 43.1% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Axsome Therapeutics Inc.

Currently, the analyst consensus on Array Biopharma is Strong Buy and the average price target is $8.67, representing a 30.2% upside.

In a report issued on November 4, Cowen & Co. also initiated coverage with a Buy rating on the stock with a $10 price target.
Phibro Animal Health (NASDAQ: PAHC)

Credit Suisse analyst Erin Wilson reiterated a Buy rating on Phibro Animal Health (NASDAQ: PAHC) today and set a price target of $29. The company’s shares opened today at $24.85.

According to TipRanks.com, Wilson is a 4-star analyst with an average return of 6.6% and a 61.2% success rate. Wilson covers the Healthcare sector, focusing on stocks such as Dentsply International Inc., Quest Diagnostics Inc., and Charles River Labs .

Phibro Animal Health has an analyst consensus of Moderate Buy, with a price target consensus of $29.